枯草杆菌二联活菌联合乳果糖治疗儿童功能性便秘远期疗效观察

目的 探讨枯草杆菌二联活菌联合乳果糖治疗儿童功能性便秘（functional constipation，FC）的远期疗效。方法 选择180例儿童FC患者，按照治疗的方式不同分为联合组、乳果糖组和妈咪爱组，每组60例。3组均给予足量饮水、合理饮食、排便习惯训练、增加活动量、心理行为治疗，乳果糖组口服乳果糖，妈咪爱组口服枯草杆菌二联活菌多维颗粒剂，联合组口服枯草杆菌二联活菌多维颗粒剂和乳果糖，疗程8周，观察大便次数、性状、排便困难及疼痛情况，比较3组停药后3个月、6个月和12个月的复发率。结果 停药3个月，联合组、乳果糖组和妈咪爱组复发率分别为10.34%、30.00%和25.49%，联合组明显低于其他两组（P<0.05）；停药6个月，联合组、乳果糖组和妈咪爱组复发率分别为18.97%、52.00%和41.18%，联合组明显低于其他两组（P<0.05）；停药12个月，联合组、乳果糖组和妈咪爱组复发率分别为24.14%、58.00%和49.02%，联合组明显低于其他两组（P<0.05）；随访3、6、12个月，联合组患儿大便次数及性状恢复、排便困难及疼痛缓解情况优于乳果糖组和妈咪爱组（P<0.05）。结论 枯草杆菌二联活菌联合乳果糖治疗儿童FC，远期疗效显著，复发率低，具有一定的临床应用价值。

Long-term efficacy of medilac-vita combined with lactulose in treatment of functional constipation in children

Objective To study the long-term efficacy of medilac-vita combined with lactulose in treatment of functional constipation (FC) in children. Methods On the basis of the same routine treatment, which consisted of defecation habit practice, increasing in number of dietary fiber, enough water drinking, suitable exercise, and psychotherapy, a total of 180 children with FC were randomly divided into three groups: medilac-vita and lactulose treatment group (combined treatment group), lactulose treatment group (lactulose group), and medilac-vita treatment group (medilac-vita group). Fecal form, frequency, difficulty, and pain in three groups after 8 weeks were observed, and the relapse rate after following up for 3 months, 6 months, and 1 year were compared. Results The relapse rates were 10.34% in combined treatment group, 30.00% in lactulose group, and 25.49% in medilac-vita group at 3 months after therapy (P<0.05); 18.97% in combined treatment group, 52.00% in lactulose group, and 41.18% in medilac-vita group at 6 months after therapy (P<0.05); 24.14% in combined treatment group, 58.00% in lactulose group, and 49.02% in medilac-vita group at 12 months after therapy (P<0.05). The frequency of defecation, normalization of the stool form, and improvement degrees of dysporia and dyschizia in combined treatment group were significantly higher in comparison with lactulose group or medilac-vita group after 3, 6, and 12 months of the treatment (P<0.05). Conclusion Medilac-vita combined with lactulose is obviously better and with low relapse rate in treatment of FC in children, which is worthy of application.